Hyperlipoprotein(a): Risk Prediction, Detection, and Treatment

Anindita Chakraborty

doi:10.26182/gxww-9z56

Hyperlipoprotein(a): Risk Prediction, Detection, and Treatment

Anindita Chakraborty

UWA Medical School

Research output: Thesis › Doctoral Thesis

266 Downloads (Pure)

Abstract

Lipoprotein(a) [Lp(a)] is an inherited risk factor for atherosclerotic cardiovascular disease (ASCVD). In spite of the significant impact of elevated Lp(a) on cardiovascular health, gaps in understanding several aspects of Lp(a) remain. To close these gaps four observational studies were designed. The results of the studies support the overall hypothesis of the thesis that elevated Lp(a) is a causal risk factor for ASCVD, can be effectively detected by cascade testing relatives of affected probands, and can be lowered by pharmacotherapy. Further studies are recommended with novel agents that could specifically lower Lp(a) in high risk patients.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Watts, Gerald, Supervisor Chan, Dick, Supervisor Pang, Jing, Supervisor
Thesis sponsors	Australian Government Research Training Program
Award date	18 Oct 2022
DOIs	https://doi.org/10.26182/gxww-9z56
Publication status	Unpublished - 2022

Access to Document

10.26182/gxww-9z56

THESIS - DOCTOR OF PHILOSOPHY - CHAKRABORTY Anindita - 2022
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a)
Chakraborty, A., Pang, J., Chan, D. C., Ellis, K. L., Hooper, A. J., Bell, D. A., Burnett, J. R., Moses, E. K. & Watts, G. F., May 2022, In: Atherosclerosis. 349, p. 219-226 8 p.
Research output: Contribution to journal › Article › peer-review
19 Link opens in a new tab Citations (Scopus)
Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)
Chakraborty, A., Chan, D. C., Ellis, K. L., Pang, J., Barnett, W., Woodward, A. M., Vorster, M., Norman, R., Moses, E. K. & Watts, G. F., 1 Jun 2022, In: American Journal of Preventive Cardiology. 10, 100343.
Research output: Contribution to journal › Article › peer-review

Open Access
File

15 Link opens in a new tab Citations (Scopus)

61 Downloads (Pure)
Effectiveness of proprotein convertase subtilisin/kexin‐9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic
Chakraborty, A., Pang, J., Chan, D. C., Barnett, W., Woodward, A. M., Vorster, M. & Watts, G. F., Jun 2021, In: Clinical Cardiology. 44, 6, p. 805-813 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
7 Link opens in a new tab Citations (Scopus)

Cite this

@phdthesis{243fdffedaea47dba2492d48b308b3ca,

title = "Hyperlipoprotein(a): Risk Prediction, Detection, and Treatment",

abstract = "Lipoprotein(a) [Lp(a)] is an inherited risk factor for atherosclerotic cardiovascular disease (ASCVD). In spite of the significant impact of elevated Lp(a) on cardiovascular health, gaps in understanding several aspects of Lp(a) remain. To close these gaps four observational studies were designed. The results of the studies support the overall hypothesis of the thesis that elevated Lp(a) is a causal risk factor for ASCVD, can be effectively detected by cascade testing relatives of affected probands, and can be lowered by pharmacotherapy. Further studies are recommended with novel agents that could specifically lower Lp(a) in high risk patients.",

keywords = "Lipoprotein(a), PCSK9mAb, Cascade testing, Lp(a), FH, ASCVD",

author = "Anindita Chakraborty",

year = "2022",

doi = "10.26182/gxww-9z56",

language = "English",

school = "The University of Western Australia",

}

TY - BOOK

T1 - Hyperlipoprotein(a): Risk Prediction, Detection, and Treatment

AU - Chakraborty, Anindita

PY - 2022

Y1 - 2022

N2 - Lipoprotein(a) [Lp(a)] is an inherited risk factor for atherosclerotic cardiovascular disease (ASCVD). In spite of the significant impact of elevated Lp(a) on cardiovascular health, gaps in understanding several aspects of Lp(a) remain. To close these gaps four observational studies were designed. The results of the studies support the overall hypothesis of the thesis that elevated Lp(a) is a causal risk factor for ASCVD, can be effectively detected by cascade testing relatives of affected probands, and can be lowered by pharmacotherapy. Further studies are recommended with novel agents that could specifically lower Lp(a) in high risk patients.

AB - Lipoprotein(a) [Lp(a)] is an inherited risk factor for atherosclerotic cardiovascular disease (ASCVD). In spite of the significant impact of elevated Lp(a) on cardiovascular health, gaps in understanding several aspects of Lp(a) remain. To close these gaps four observational studies were designed. The results of the studies support the overall hypothesis of the thesis that elevated Lp(a) is a causal risk factor for ASCVD, can be effectively detected by cascade testing relatives of affected probands, and can be lowered by pharmacotherapy. Further studies are recommended with novel agents that could specifically lower Lp(a) in high risk patients.

KW - Lipoprotein(a)

KW - PCSK9mAb

KW - Cascade testing

KW - Lp(a)

KW - FH

KW - ASCVD

U2 - 10.26182/gxww-9z56

DO - 10.26182/gxww-9z56

M3 - Doctoral Thesis

ER -

Hyperlipoprotein(a): Risk Prediction, Detection, and Treatment

Abstract

Access to Document

Fingerprint

Research output

Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a)

Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)

Effectiveness of proprotein convertase subtilisin/kexin‐9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic

Cite this